Chart of the Week: 3x Improvement in Likelihood of Approval

by

In May we released a report co-authored with BIO and BioMedTracker. One of the key take-aways from the report is that patient selection biomarkers, if used successfully, can triple the Likelihood of Approval (LOA) for clinical studies.  Here is the data:

Biomarker_triple_clinical_trial_success_rates.png

Share this Image On Your Site

Please include attribution to amplion.com with this graphic.

3x Improvements in Clinical Trial Likelihood of Approval

PageLines

Real-Time COVID R&D Tracking

As COVID-19 infections continue to spread, organizations with technologies or devices that can support new drug, vaccine, or test development have a life-saving contribution to make. The Amplion Intelligence Platform can alert you to new COVID-19 trial activities in real-time and automatically match you to partners who need your unique capabilities immediately. It’s already tomorrow somewhere, so let us help you start today.  Learn More

Request Access